Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

Marco Vitolo, Vincenzo L. Malavasi, Marco Proietti, Igor Diemberger, Laurent Fauchier, Francisco Marin, Michael Nabauer, Tatjana S. Potpara, Gheorghe-Andrei Dan, Zbigniew Kalarus, Luigi Tavazzi, Aldo Pietro Maggioni, Deirdre A. Lane, Gregory Y.H. Lip, Giuseppe Boriani*, ESC-EHRA EORP-AF Long-Term General Registry Investigators, Albert Marni Joensen (Medlem af forfattergruppering), Anders Gammelmark (Medlem af forfattergruppering), Lars Hvilsted Rasmussen (Medlem af forfattergruppering), Pia Thisted Dinesen (Medlem af forfattergruppering)Sam Riahi (Medlem af forfattergruppering), Stine Krogh Venø (Medlem af forfattergruppering), Bodil Ginnerup Sørensen, Anne Marie Korsgaard (Medlem af forfattergruppering), Karen Petrea Andersen (Medlem af forfattergruppering), Camilla Fragtrup Hellum (Medlem af forfattergruppering)


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

4 Citationer (Scopus)


BACKGROUND: Cardiac troponins (cTn) have been reported to be predictors for adverse outcomes in atrial fibrillation (AF), patients, but their actual use is still unclear.

AIM: To assess the factors associated with cTn testing in routine practice and evaluate the association with outcomes.

METHODS: Patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry were stratified into 3 groups according to cTn levels as (i) cTn not tested, (ii) cTn in range (≤99th percentile), (iii) cTn elevated (>99th percentile). The composite outcome of any thromboembolism /any acute coronary syndrome/cardiovascular (CV) death, defined as Major Adverse Cardiovascular Events (MACE) and all-cause death were the main endpoints.

RESULTS: Among 10 445 AF patients (median age 71 years, 40.3% females) cTn were tested in 2834 (27.1%). cTn was elevated in 904/2834 (31.9%) and in-range in 1930/2834 (68.1%) patients. Female sex, in-hospital enrollment, first-detected AF, CV risk factors, history of coronary artery disease, and atypical AF symptoms were independently associated with cTn testing. Elevated cTn were independently associated with a higher risk for MACE (Model 1, hazard ratio [HR] 1.74, 95% confidence interval [CI] 1.40-2.16, Model 2, HR 1.62, 95% CI 1.28-2.05; Model 3 HR 1.76, 95% CI 1.37-2.26) and all-cause death (Model 1, HR 1.45, 95% CI 1.21-1.74; Model 2, HR 1.36, 95% CI 1.12-1.66; Model 3, HR 1.38, 95% CI 1.12-1.71).

CONCLUSIONS: Elevated cTn levels were associated with an increased risk of all-cause mortality and adverse CV events. Clinical factors that might enhance the need to rule out CAD were associated with cTn testing.

TidsskriftEuropean Journal of Internal Medicine
Sider (fra-til)45-56
StatusUdgivet - maj 2022

Bibliografisk note

Copyright © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.


Dyk ned i forskningsemnerne om 'Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry'. Sammen danner de et unikt fingeraftryk.